Nextleaf Solutions Receives a CBD Extraction Patent From the Canadian Intellectual Property Office

Article by Sean Mason, Proactive

Nextleaf Solutions Ltd (CSE:OILS) (OTCMKTS:OILFF) reported that it has been granted a patent for the acetylation of cannabinoids (CBD), as well as the subsequent refinement of CBD-O-Acetate using a proprietary extraction and distillation technique, from the Canadian intellectual property office.

Nextleaf noted that it now owns 12 US patents and 70 patents globally for the extraction, purification, and delivery of cannabinoids, which is says represents the second-largest patent portfolio among all cannabis companies.

“We expect the results of the 2020 US elections will have a transformational effect on the commercial value of our US patent portfolio,” Nextleaf Solutions CEO Paul Pedersen said in a statement.

He added: “The world’s largest cannabis company launching the industry’s first patent infringement lawsuit against GW Pharma on December 22, 2020, demonstrates the value of patents and intellectual property in the cannabis industry.”

Nextleaf said it believes an orally-consumable CBD metabolic prodrug produced under its patented process for acetylating cannabidiol will enhance the therapeutic potency of CBD, as it enables the standardization of a more potent analog of CBD through targeted drug delivery.

It added that prodrugs utilize various physical and chemical modifications to improve features of active drugs, as it maintains the integrity of the molecule and its ability to deliver drugs to precisely-targeted areas in the body, which may increase efficacy for desired outcomes.

Nextleaf noted that it already owns US patents for the acetylation of THC, and the acetylation of CBD and suggested that its patent portfolio and Health Canada licenses for cannabis processing and research presents an entry point for pharmaceutical firms looking to manufacture cannabinoid prodrugs in a federally legal jurisdiction.

Read the full article here.